Research Comparison
LL-37 (Human Cathelicidin) vs VIP (Vasoactive Intestinal Peptide)
A side-by-side research comparison of LL-37 (Human Cathelicidin) and VIP (Vasoactive Intestinal Peptide) drawn from Cobalt Peptides' peptide database records.
LL-37 (Human Cathelicidin)
LL-37 is the only known human cathelicidin antimicrobial peptide, consisting of 37 amino acids and derived from the precursor protein hCAP18. It plays a critical role in innate immunity, exhibiting broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while also modulating inflammatory responses and promoting tissue repair. It is most commonly studied in topical applications for wound healing, where it provides both antimicrobial protection and regenerative support. Clinical and experimental data show significant improvements in chronic wound healing, though systemic use remains less well characterized.
VIP (Vasoactive Intestinal Peptide)
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide with potent anti-inflammatory, immunomodulatory, and neuroprotective properties. Acting through VPAC1 and VPAC2 receptors, VIP regulates immune function, vascular tone, circadian rhythms, and neurological activity. VIP has been extensively studied in inflammatory, pulmonary, and neurological conditions. Intranasal delivery enables direct CNS access via olfactory and trigeminal pathways, while systemic administration influences immune and vascular systems. It is particularly notable in research involving chronic inflammatory response syndrome (CIRS), respiratory dysfunction, and neuroimmune regulation.